The coronavirus vaccine race now features three front runners with clinical data, and at least one boasts impressive T-cell responses.
A small trial of inhaled interferon marks a 30-fold increase in Synairgen stock since January, but the endpoints warrant scrutiny.
The UK big pharma group unveils funding and a clinical programme that could overshadow the efforts of its biotech rival.
On the back of coronavirus mania, Moderna, a $30bn company heavily funded by the US government, taps investors for $1.3bn.
Moderna becomes the latest coronavirus vaccine player to act on the need for a major manufacturing push.